178 related articles for article (PubMed ID: 20640601)
1. The clinical significance of MIB-1 labeling index in pituitary adenomas.
Chacko G; Chacko AG; Kovacs K; Scheithauer BW; Mani S; Muliyil JP; Seshadri MS
Pituitary; 2010 Dec; 13(4):337-44. PubMed ID: 20640601
[TBL] [Abstract][Full Text] [Related]
2. The clinical and pathological significance of nitric oxide synthase in human pituitary adenomas: a comparison with MIB-1.
Onishi K; Kamida T; Momii Y; Abe T; Fujiki M
Endocrine; 2014 May; 46(1):154-9. PubMed ID: 24008756
[TBL] [Abstract][Full Text] [Related]
3. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
4. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas.
Mastronardi L; Guiducci A; Puzzilli F
BMC Cancer; 2001; 1():12. PubMed ID: 11570981
[TBL] [Abstract][Full Text] [Related]
5. Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression.
Widhalm G; Wolfsberger S; Preusser M; Fischer I; Woehrer A; Wunderer J; Hainfellner JA; Knosp E
J Neurosurg; 2009 Sep; 111(3):563-71. PubMed ID: 18991501
[TBL] [Abstract][Full Text] [Related]
6. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
[TBL] [Abstract][Full Text] [Related]
7. Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody.
Pizarro CB; Oliveira MC; Coutinho LB; Ferreira NP
Braz J Med Biol Res; 2004 Feb; 37(2):235-43. PubMed ID: 14762579
[TBL] [Abstract][Full Text] [Related]
8. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
Matsuyama J
Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
[TBL] [Abstract][Full Text] [Related]
9. Pathobiology of pituitary adenomas and carcinomas.
Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
[TBL] [Abstract][Full Text] [Related]
10. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody.
Lath R; Chacko G; Chandy MJ
Neurol India; 2001 Jun; 49(2):144-7. PubMed ID: 11447433
[TBL] [Abstract][Full Text] [Related]
11. Adrenocorticotropic hormone secreting pituitary adenomas: analysis of growth fraction using the MIB-1 antibody.
Mastronardi L; Guiducci A; Spera C; Puzzilli F; Liberati F; Ruggeri A; Peciarolo A
Tumori; 2000; 86(3):229-32. PubMed ID: 10939604
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation parameters and apoptosis indices in pituitary macroadenomas.
Ruggeri RM; Costa G; Simone A; Campennì A; Sindoni A; Ieni A; Cavallari V; Trimarchi F; Curtò L
J Endocrinol Invest; 2012 May; 35(5):473-8. PubMed ID: 21897111
[TBL] [Abstract][Full Text] [Related]
13. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L
Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody.
Mastronardi L; Guiducci A; Spera C; Puzzilli F; Liberati F; Maira G
J Clin Pathol; 1999 Feb; 52(2):107-11. PubMed ID: 10396237
[TBL] [Abstract][Full Text] [Related]
15. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas.
Jaffrain-Rea ML; Di Stefano D; Minniti G; Esposito V; Bultrini A; Ferretti E; Santoro A; Faticanti Scucchi L; Gulino A; Cantore G
Endocr Relat Cancer; 2002 Jun; 9(2):103-13. PubMed ID: 12121834
[TBL] [Abstract][Full Text] [Related]
16. Role of PROPELLER diffusion-weighted imaging and apparent diffusion coefficient in the evaluation of pituitary adenomas.
Mahmoud OM; Tominaga A; Amatya VJ; Ohtaki M; Sugiyama K; Sakoguchi T; Kinoshita Y; Takeshima Y; Abe N; Akiyama Y; El-Ghoriany AI; Abd Alla AK; El-Sharkawy MA; Arita K; Kurisu K; Yamasaki F
Eur J Radiol; 2011 Nov; 80(2):412-7. PubMed ID: 20580505
[TBL] [Abstract][Full Text] [Related]
17. Atypical pituitary adenoma: a clinicopathologic case series.
Rutkowski MJ; Alward RM; Chen R; Wagner J; Jahangiri A; Southwell DG; Kunwar S; Blevins L; Lee H; Aghi MK
J Neurosurg; 2018 Apr; 128(4):1058-1065. PubMed ID: 28598278
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic correlates of giant pituitary adenomas.
Chacko G; Chacko AG; Lombardero M; Mani S; Seshadri MS; Kovacs K; Scheithauer BW
J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
[TBL] [Abstract][Full Text] [Related]
20. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index.
Tanaka Y; Hongo K; Tada T; Sakai K; Kakizawa Y; Kobayashi S
J Neurosurg; 2003 Feb; 98(2):359-65. PubMed ID: 12593623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
